LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

Home・Lista de Ações・Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals Inc

Fechado

SetorSaúde

638.17 -0.53

Comprar Vender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

633.36

Máximo

642.52

Indicadores-chave
By Trading Economics
Rendimento	-117M 727M
Vendas	-279M 3.6B
P/E Médio do Setor	15.384 49.701
EPS	9.47
Rendimento de Dividendos	0.51
Margem de lucro	20.17
Funcionários	15,343
EBITDA	-234M 967M

Recomendações
By TipRanks
Recomendações	Comprar
Previsão para 12 meses	+29.13% upside

Dividendos
By Dow Jones
Rendimento de Dividendos Médio do Setor	0.51% 2.39%
Próximos Ganhos	31 de jul. de 2026

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	-12B 66B
Abertura anterior	638.7
Fecho anterior	638.17

Pontuação Técnica

By Trading Central

Confiança

Very Strong Bearish Evidence

542.44 / 599.76 Suporte e Resistência

Regeneron Pharmaceuticals Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

1 de ago. de 2025, 11:33 UTC

Ganhos

Regeneron 2Q Revenue, Adjusted EPS Top Estimates

29 de abr. de 2026, 12:01 UTC

Ganhos

Regeneron Earnings Beat Expectations. Upcoming Cancer Data Matter More for the Stock. -- Barrons.com

23 de abr. de 2026, 21:48 UTC

Aquisições, Fusões, Aquisições de Empresas

Regeneron Shares Up on Trump Drug Pricing Deal -- Barrons.com

11 de mar. de 2026, 11:02 UTC

Conversa de Mercado

Sanofi, Regeneron's Eczema Drug Might Face Competition From Pfizer -- Market Talk

14 de dez. de 2025, 08:30 UTC

Aquisições, Fusões, Aquisições de Empresas

Kymera Had a Big Week. This Secretive Hedge Fund Bought $172 Million of Its Stock. -- Barrons.com

1 de ago. de 2025, 13:16 UTC

Ganhos

Regeneron Stock Is Rising on Earnings. This Sanofi Collaboration Is Helping. -- Barrons.com

1 de ago. de 2025, 12:40 UTC

Ganhos

Regeneron Stock Is Rising on Earnings. This Sanofi Collaboration Is Helping. -- Barrons.com

1 de ago. de 2025, 10:41 UTC

Ganhos

Regeneron Now Sees 2025 Adjusted R&D $5.1B-$5.2B; Had Seen $5B-$5.2B >REGN

1 de ago. de 2025, 10:41 UTC

Ganhos

Regeneron Now Sees 2025 Capital Spending $880M-$950M; Had Seen $850M-$950M >REGN

1 de ago. de 2025, 10:40 UTC

Ganhos

Regeneron Now Sees 2025 Adjusted Gross Margin on Net Product Sales About 86%; Had Seen 86%-87% >REGN

1 de ago. de 2025, 10:38 UTC

Ganhos

Regeneron: Odronextamab Application Also Impacted by Site Inspection >REGN

1 de ago. de 2025, 10:37 UTC

Ganhos

Regeneron Gets FDA Complete Response Letter for Odronextamab in Follicular Lymphoma >REGN

1 de ago. de 2025, 10:35 UTC

Ganhos

Regeneron: Anticipate Expeditious Resolution of Filling Issues for Eylea HD >REGN

1 de ago. de 2025, 10:34 UTC

Ganhos

Regeneron Cites Observations From FDA General Site Inspection at Filler for Eylea HD >REGN

1 de ago. de 2025, 10:33 UTC

Ganhos

Regeneron Sees FDA Approvals Delayed for Eylea HD Indications With August Target Actio Dates >REGN

1 de ago. de 2025, 10:32 UTC

Ganhos

Regeneron Pharma: About 45 Product Candidates in Clinical Development >REGN

1 de ago. de 2025, 10:31 UTC

Ganhos

Regeneron Pharma 2Q Eylea HD, Eylea U.S. Net Sales Fell 25% to $1.15B >REGN

1 de ago. de 2025, 10:31 UTC

Ganhos

Regeneron Pharma: 2Q Dupixent Global Net Sales Recorded by Sanofi Rose 22% to $4.34B >REGN

1 de ago. de 2025, 10:30 UTC

Ganhos

Regeneron Pharma 2Q Adj EPS $12.89 >REGN

1 de ago. de 2025, 10:30 UTC

Ganhos

Regeneron Pharma 2Q Rev $3.68B >REGN

1 de ago. de 2025, 10:30 UTC

Ganhos

Regeneron Pharma 2Q EPS $12.81 >REGN

1 de ago. de 2025, 10:30 UTC

Ganhos

Regeneron Pharma 2Q Net $1.39B >REGN

13 de jun. de 2025, 21:42 UTC

Aquisições, Fusões, Aquisições de Empresas

Anne Wojcicki Wins Bidding for 23andMe -- 2nd Update

13 de jun. de 2025, 20:45 UTC

Aquisições, Fusões, Aquisições de Empresas

23andMe: TTAM Makes Binding Commitments for Additional Consumer Protections and Privacy Safeguards

13 de jun. de 2025, 20:34 UTC

Aquisições, Fusões, Aquisições de Empresas

Anne Wojcicki Wins Bidding for 23andMe -- Update

13 de jun. de 2025, 20:14 UTC

Aquisições, Fusões, Aquisições de Empresas

Nonprofit Controlled By 23andMe Co-Founder Anne Wojcicki Would Buy the DNA-Testing Company for $305 Million -- WSJ

13 de jun. de 2025, 20:14 UTC

Aquisições, Fusões, Aquisições de Empresas

Anne Wojcicki Wins Bidding for 23andMe -- WSJ

13 de jun. de 2025, 20:14 UTC

Aquisições, Fusões, Aquisições de Empresas

Regeneron Walks Away From 23andMe Acquisition After Wojcicki's Higher Bid -- WSJ

5 de jun. de 2025, 01:41 UTC

Aquisições, Fusões, Aquisições de Empresas

23andMe's Former CEO Pushes Purchase Price Nearly $50 Million Higher -- WSJ

30 de mai. de 2025, 08:58 UTC

Ações em Alta

Stocks to Watch Friday: Dell, Marvell, Gap, Ulta -- WSJ

Comparação entre Pares

Variação de preço

Regeneron Pharmaceuticals Inc Previsão

Preço-alvo

By TipRanks

29.13% parte superior

Previsão para 12 meses

Média 829.77 USD 29.13%

Máximo 995 USD

Mínimo 641 USD

Com base em 22 analistas de Wall Street que oferecem metas de preço de 12 meses para Regeneron Pharmaceuticals Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

22 ratings

Comprar

Manter

Vender

Com base em 22 analistas que deram avaliações de ações para Regeneron Pharmaceuticals Inc - Dist nos últimos 3 meses.

Pontuação Técnica

By Trading Central

542.44 / 599.76Suporte e Resistência

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

All events are bearish.

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

Sobre Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types; and with Sonoma Biotherapeutics, Inc. to discover, develop, and commercialize engineered regulatory T cell therapies. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.